Mesoblast's (MSB) phase three COVID-19 trial has been approved to continue by the Data Safety Monitoring Board (DSMB). Big tick The trial tests MSB's remestemcel-L treatment in hospitalised COVID-19 patients suffering acute respiratory distress syndrome (ARDS) — the primary cause of death associated with the virus. Following the second interim analysis of the trial, the DSMB has recommended the study continue based on a review of the trial endpoints. So far, 135 patients have been enrolled out of a planned 300.